Clinical Trial Update: Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for the ATSA trial evaluating absorbed tumor dose in peptide receptor radionuclide therapy using long-acting somatostatin analogues in n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Neoplasm
• Neuroendocrine Tumor

Drugs mentioned

• Long-acting somatostatin analogue (somatostatin analogue)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1 | Phase 2, Phase 3 | Status: RECRUITING